Journal: bioRxiv
Article Title: Targeting Semaphorin 7a signaling in preclinical models of estrogen receptor-positive breast cancer
doi: 10.1101/2025.05.21.655360
Figure Lengend Snippet: A) Representative immunoblot for pAKT (S473), AKT and GAPDH in TC11 shCtrl and shSEMA7A (KD#1 and KD#2) cell lines. Bar graph: ratio of pAKT to total AKT. Ordinary one-way ANOVA with Tukey’s multiple comparisons test. B) Representative immunoblot for pAKT (S473), AKT and GAPDH in TC11 shCtrl and shSEMA7A KD#2 cell lines after treatment for 24 hours with 20 μg/mL purified rSEMA7A, or conditioned media from SEMA7A OE cells (S7OE CM). Bar graph: ratio of pAKT to total AKT. Ordinary one-way ANOVA with Tukey’s multiple comparisons test. C) Representative immunoblot for pAKT (S473), AKT and GAPDH in TC11 WT cell lysates after treatment for 1 hour with 20 μg/mL rSEMA7A, 50 μM RGDS peptide, or both. Bar graph: ratio of pAKT to total AKT. Ordinary one-way ANOVA with Tukey’s multiple comparisons test. Error bars are mean +/- SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Article Snippet: For RGDS experiments, RGDS peptide (Tocris Bioscience; Cat#3498, 50uM in milliQ H 2 O) or control (milliQ H 2 O) was added to culture media for 1 hour prior to making cell lysates.
Techniques: Western Blot, Purification